Jennifer A. Woyach, MD

Articles by Jennifer A. Woyach, MD

Dr Woyach on When to Initiate Subsequent Therapy in Patients With CLL

ByJennifer A. Woyach, MD

September 23rd 2025

Jennifer A. Woyach, MD, discusses when to initiate subsequent therapy in patients with CLL.

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

ByJennifer A. Woyach, MD

September 14th 2020

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

ByJennifer A. Woyach, MD

September 11th 2020

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

Dr. Woyach on the Role of Acalabrutinib in CLL

ByJennifer A. Woyach, MD

September 10th 2020

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Dr. Woyach on Remaining Sequencing Questions in CLL

ByJennifer A. Woyach, MD

September 9th 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

ByJennifer A. Woyach, MD

August 14th 2020

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

ByJennifer A. Woyach, MD

August 11th 2020

Jennifer Woyach, MD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Woyach on Phase II Trial of MOR208 Trial in CLL

ByJennifer A. Woyach, MD

February 17th 2017

Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.